Management of Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma
- PMID: 35715142
- PMCID: PMC11254341
- DOI: 10.1016/j.soc.2022.03.006
Management of Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma
Abstract
Undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) are genomically complex tumors commonly diagnosed in the extremities or trunk of elderly patients. They likely represent a spectrum of disease differentiated by myxoid stroma and curvilinear vessels observed in MFS but not in UPS. Limb-sparing surgery is the standard of care although the infiltrative nature of MFS mandates wider resection margins than are necessary for UPS. UPS are conversely associated with high risks of distal recurrence, often prompting recommendations for adjuvant chemotherapy. In both histologies, anthracycline-based therapies or gemcitabine and docetaxel are used to manage advanced disease; immunotherapy may be of benefit in a subset of patients.
Keywords: Limb-sparing surgery; Malignant fibrous histiocytoma; Myxofibrosarcoma; Soft tissue sarcoma; Undifferentiated pleomorphic sarcoma; systemic therapy.
Copyright © 2022 Elsevier Inc. All rights reserved.
Figures



References
-
- Cheah AL, Billings SD, Goldblum JR, Carver P, Tanas MZ, Rubin BP. STAT6 rabbit monoclonal antibody is a robust diagnostic tool for the distinction of solitary fibrous tumour from its mimics. Pathology 2014;46(5):389–95. - PubMed
-
- Doyle LA, Vivero M, Fletcher CD, Mertens F, Hornick JL. Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics. Mod Pathol 2014;27(3):390–5. - PubMed
-
- Dry SMaF, Leiomyosarcoma S. WHO classification of Tumours of soft tissue and bone. 5th edition. IARC; 2020. p. 195–7.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical